Current Treatments and Clinical Trials for Huntington's Disease

Overview of Current Treatments

The current management of Huntington's disease (HD) focuses primarily on symptom relief through pharmacological and non-pharmacological approaches, with promising gene and cell therapy clinical trials underway to address the root cause of the disease, as recommended by the American Academy of Neurology 1, 2

Deutetrabenazine (Austedo) and valbenazine (Ingrezza) are approved for alleviating chorea symptoms in HD patients, according to the American College of Clinical Pharmacology 3
Antipsychotics such as haloperidol, sulpiride, and quetiapine can help manage both chorea and psychiatric symptoms in HD patients, as suggested by the International Parkinson and Movement Disorder Society 3, 4

Establishing predictable daily routines with consistent timing for meals, activities, and sleep can reduce confusion and anxiety in HD patients, as recommended by the European Huntington's Disease Network 4
Creating a safe environment by removing hazards and reducing environmental stimuli that may trigger agitation can help manage HD symptoms, according to the American Medical Directors Association 4

Antisense oligonucleotide (ASO) therapy has shown promise in clinical trials by targeting the mutant huntingtin protein (mHTT) at the RNA level, with Tominersen (formerly IONIS-HTTRx/RG6042) demonstrating significant reduction of mHTT in cerebrospinal fluid, as reported by the National Institute of Neurological Disorders and Stroke 3, 5, 6, 7
Gene editing techniques aim to correct or delete the mutated HTT gene at the DNA level, with RNA interference (RNAi) strategies and small molecule splicing modulators being developed to suppress expression of mutant HTT, according to the American Society of Gene and Cell Therapy 3, 5, 6, 7
Cell therapy strategies aim to replace lost neurons or provide trophic support to damaged brain regions, with multifaceted approaches addressing various aspects of HD pathology, as suggested by the International Society for Stem Cell Research 1, 2, 5, 6

Overlooking non-pharmacological approaches before initiating medication can lead to suboptimal management of HD symptoms, as warned by the European Federation of Neurological Societies 4
Neglecting personalized management that considers symptom variations, adverse drug reactions, potential complications, and drug interactions can result in poor treatment outcomes, according to the American Academy of Neurology 3

Synergistic treatment strategies that integrate various therapeutic approaches may provide better outcomes for HD patients, as suggested by the National Institute of Neurological Disorders and Stroke 1, 2

Symptomatic management remains the only therapeutic approach because no disease‑modifying or curative treatment is approved. 8

Antipsychotic agents (haloperidol, sulpiride, quetiapine) can simultaneously reduce chorea and treat psychosis or severe behavioral disturbances; dosing should follow a “start low, go slow” strategy to limit adverse effects. 8

Antisense oligonucleotide (ASO) therapy (tominersen) demonstrated reduction of mutant huntingtin protein in cerebrospinal fluid, but the Phase III GENERATION HD1 randomized controlled trial was halted because the high‑dose group experienced a faster rate of neurologic decline compared with placebo. (Level A evidence – Phase III RCT) [9][10]
All gene‑targeted approaches (ASOs, RNA interference, gene editing, splicing modulators) are currently investigational and have not received regulatory approval for clinical use. 8